Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod add-on to dimethyl fumarate in active relapsing multiple sclerosis
2012-000541-12Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2016
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ponesimod add-on with Placebo add-on (2 arms). Primary endpoint: Annualized relapse rate. Started Jul 2016; status: terminated.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-000541-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000541-12.